Lyell Immunopharma (LYEL) EBT Margin Growth (3y) (2023 - 2026)
Lyell Immunopharma (LYEL) EBT Margin Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9,237.00 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 441.00 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -408.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -120.00 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -503.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -503.26 Mn |
| Dec 31, 2025 | -241.12 Mn |
| Sep 30, 2025 | 559.81 Mn |
| Jun 30, 2025 | -144.30 Mn |
| Mar 31, 2025 | -180.95 Mn |
| Dec 31, 2024 | -509.43 Mn |
| Sep 30, 2024 | -36.37 Mn |
| Jun 30, 2024 | -98.94 Mn |
| Mar 31, 2024 | -249.47 Mn |
| Dec 31, 2023 | -235.40 Mn |
| Sep 30, 2023 | -27.67 Mn |
| Jun 30, 2023 | -33.30 Mn |